KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Cost of Revenue: 2020-2024

Historic Cost of Revenue for Moderna (MRNA) over the last 5 years, with Dec 2024 value amounting to $1.5 billion.

  • Moderna's Cost of Revenue fell 59.73% to $207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 30.17%. This contributed to the annual value of $1.5 billion for FY2024, which is 68.80% down from last year.
  • According to the latest figures from FY2024, Moderna's Cost of Revenue is $1.5 billion, which was down 68.80% from $4.7 billion recorded in FY2023.
  • In the past 5 years, Moderna's Cost of Revenue registered a high of $5.4 billion during FY2022, and its lowest value of $8.0 million during FY2020.
  • For the 3-year period, Moderna's Cost of Revenue averaged around $3.9 billion, with its median value being $4.7 billion (2023).
  • In the last 5 years, Moderna's Cost of Revenue surged by 32,612.50% in 2021 and then plummeted by 68.80% in 2024.
  • Yearly analysis of 5 years shows Moderna's Cost of Revenue stood at $8.0 million in 2020, then surged by 32,612.50% to $2.6 billion in 2021, then soared by 106.95% to $5.4 billion in 2022, then fell by 13.35% to $4.7 billion in 2023, then tumbled by 68.80% to $1.5 billion in 2024.